Curtis L. Scribner

Biography

 Curtis L. Scribner, MD, joined Olatec’s Drug Development Team.  Dr. Scribner, who serves as Chief Medical Officer, was appointed to Olatec’s Scientific Advisory Board in November 2014. Dr. Scribner has been contributing leading expertise to the clinical development of dapansutrile in the design and conduct of Olatec’s human clinical trials, and acts as a member of the Safety Committee for Olatec’s clinical trials.  Dr. Scribner is an independent consultant and was previously Senior Vice President of Medical and Regulatory Affairs at RRD International, LLC.  Dr. Scribner is a board certified physician in internal medicine and has direct experience running large clinical programs.  He joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer.  Previously, Dr. Scribner was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous NDA, BLA, IND, IDE, 510(k), PMA and MAA applications.  Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics.  Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management and a BA in Biology from Grinnell College.

Research Interest

 Orthopaedics